Mankind Pharma Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Mankind Pharma acquires Rivotril brand for India, reinforcing focus on chronic CNS therapies".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma has acquired the Rivotril brand from Roche for the Indian market, gaining exclusive rights to manufacture, market, and distribute the product domestically. Rivotril is the original innovator brand of clonazepam, widely prescribed for neurological and psychiatric conditions, and is regarded as a 'Textbook brand' with strong recall among specialists. The acquisition strengthens Mankind's central nervous system (CNS) and chronic therapy portfolio, building on its earlier purchase of Bharat Serums and Vaccines. The company plans to leverage its 17,700+ strong field force and reach across over 5 lakh doctors to drive wider access and explore future line extensions in the CNS segment.
This acquisition reinforces Mankind Pharma's strategic shift toward chronic and specialty therapies, which are higher-margin and more sustainable revenue streams. For shareholders, it signals continued portfolio expansion and deeper penetration into the CNS segment, potentially supporting long-term growth, though deal financials were not disclosed.